

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Accuracy of the ELITE MGB® assays for the detection of carbapenemases, CTX-M, Staphylococcus aureus and mecA/C genes directly from respiratory samples**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1722507> since 2020-06-16T19:30:36Z

*Published version:*

DOI:10.1016/j.jhin.2019.12.025

*Terms of use:*

Open Access


Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

# Journal Pre-proof

Accuracy of the ELITe MGB® assays for the detection of carbapenemases, CTX-M, *Staphylococcus aureus* and *mecA/C* genes directly from respiratory samples

Matteo Boattini, Gabriele Bianco, Marco Iannaccone, Lorena Charrier, André Almeida, Gianfranco De Intinis, Rossana Cavallo, Cristina Costa



PII: S0195-6701(20)30002-5

DOI: <https://doi.org/10.1016/j.jhin.2019.12.025>

Reference: YJHIN 5883

To appear in: *Journal of Hospital Infection*

Received Date: 24 October 2019

Accepted Date: 30 December 2019

Please cite this article as: Boattini M, Bianco G, Iannaccone M, Charrier L, Almeida A, De Intinis G, Cavallo R, Costa C, Accuracy of the ELITe MGB® assays for the detection of carbapenemases, CTX-M, *Staphylococcus aureus* and *mecA/C* genes directly from respiratory samples, *Journal of Hospital Infection*, <https://doi.org/10.1016/j.jhin.2019.12.025>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Accuracy of the ELITE MGB<sup>®</sup> assays for the detection of carbapenemases, CTX-M, *Staphylococcus aureus* and *mecA/C* genes directly from respiratory samples

Matteo Boattini<sup>1\*</sup>, Gabriele Bianco<sup>1\*</sup>, Marco Iannaccone<sup>1</sup>, Lorena Charrier<sup>2</sup>, André Almeida<sup>3,4</sup>, Gianfranco De Intinis<sup>1</sup>, Rossana Cavallo<sup>1</sup>, Cristina Costa<sup>1</sup>

<sup>1</sup>Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy

<sup>2</sup>Department of Public Health and Paediatrics, University of Torino, Turin, Italy

<sup>3</sup>Department of Internal Medicine 4, Hospital de Santa Marta, Central Lisbon Hospital Centre, Lisbon, Portugal

<sup>4</sup>NOVA Medical School, Universidade Nova de Lisboa, Campo dos Mártires da Pátria 130, 1169-056, Lisbon, Portugal

\* These authors equally contributed to this work

CORRESPONDING AUTHOR: Matteo Boattini

E-mail: [matteo.boattini@unito.it](mailto:matteo.boattini@unito.it)

Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Corso Bramante 88/90, 10126, Turin, Italy

Tel: +390116335948

## Summary

### Introduction

Bacterial lower respiratory tract infections (BLRTI) may represent serious clinical conditions which can lead to respiratory failure, ICU admission and high hospital costs. The detection of carbapenemase- and extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Enterobacterales*, as well as methicillin-resistant *Staphylococcus aureus* (MRSA), has become a major issue especially in health care associated infections. This study aimed to determine whether molecular assays could detect genes encoding carbapenemases, ESBL and MRSA, directly from respiratory samples, so as to expedite appropriate therapy and infection control for patients with BLRTI.

### Methods

The CRE, ESBL and MRSA/SA ELITE MGB<sup>®</sup> assays were performed directly on 354 respiratory specimens sampled from 318 patients admitted with BLRTI. Molecular results were compared to routine culture-based diagnostics results.

### Results

Positive (PPV) and negative (NPV) predictive values of the CRE ELITE MGB<sup>®</sup> kit were 75.9% [IC 95%: 60.3-86.7] and 100%, respectively. PPV and NPV of the ESBL ELITE MGB<sup>®</sup> kit were 80.8% [IC 95%: 63.6-91] and 99.1% [IC 95%: 96.6-99.8], respectively. PPV and NPV predictive values of the MRSA/SA ELITE MGB<sup>®</sup> kit were 91.7% [IC 95%: 73.7-97.7]/100% and 98.3% [IC 95%: 89.8-99.3]/96.8% [IC 95%: 81.6-99.5], respectively.

### Discussion

Validity assessment of molecular assays detecting the main antibiotic resistance genes directly from respiratory samples showed a high accuracy when compared to culture-based results. Molecular assays detecting the main carbapenemase, ESBL, *S. aureus* and methicillin resistance encoding genes provide an interesting tool with potential to expedite optimization of antibiotic therapy and infection control practices in patients with BLRTI.

**Keywords:** Antibiotic resistance genes; Molecular assay; Bronchoalveolar lavage fluid; Antimicrobial stewardship; respiratory samples; pneumonia

Journal Pre-proof

## Introduction

Bacterial lower respiratory tract infections (BLRTI) including bronchitis, pneumonia, as well as infectious exacerbations in chronic lung disease can represent serious clinical conditions which can lead to respiratory failure, ICU admission, prolonged admissions and high hospital costs [1-7]. Patients admitted with BLRTI are frequently prescribed broad-spectrum empirical antibiotics; timely pathogen identification is necessary to support antibiotic stewardship and therefore reduce the risk of selection of antibiotic resistance. Detection of carbapenemase- and extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Enterobacterales* (EB) and methicillin-resistant *Staphylococcus aureus* (MRSA) has important implications for both antimicrobial therapy and infection control, especially in health care associated infections.

A positive microbiological diagnosis in BLRTI may only be made in approximately 30% of cases [8] and, since commensal and colonizing microorganisms complicate the analysis, conventional phenotypic diagnostics for respiratory samples typically takes around 48–72 h, hampering antimicrobial stewardship. Molecular tests for genes encoding carbapenemases, ESBLs and MRSA have been successfully applied directly to blood culture samples [9,10] but there is limited published evidence about their performance on respiratory samples [11-15].

The ELITe InGenius<sup>®</sup> (ELITeTechGroup Molecular Diagnostics, Turin, Italy) platform is an integrated system that automatically performs nucleic acid extraction, real-time PCR, and interpretation of results in less than 3 h. The CRE and ESBL ELITe MGB<sup>®</sup> kits are qualitative multiplex real-time PCR assays for the detection of the most prevalent carbapenemase and ESBL encoding genes in EB. The CRE ELITe MGB<sup>®</sup> Kit detects *bla*<sub>KPC-like</sub>, metallo  $\beta$ -lactamase (i.e. *bla*<sub>NDM-like</sub>, *bla*<sub>VIM-like</sub>, *bla*<sub>IMP-like</sub>), and *bla*<sub>OXA-48-like</sub> genes; the ESBL ELITe MGB<sup>®</sup> kit detects *bla*<sub>CTX-Ms</sub> genes belonging to groups 1 (including CTX-M-15) and 9 (including CTX-M-14). The MRSA/SA ELITe MGB<sup>®</sup> kit is a multiplex assay that simultaneously detects a conserved sequence of the *S. aureus*, *mecA* gene and its homologue *mecA*<sub>LG251</sub> (*mecC*).

The aim of this study was to evaluate the performance of CRE, ESBL and MRSA/SA ELITE MGB<sup>®</sup> assays directly on respiratory samples, including comparing real-time PCR cycle threshold (Ct) values with bacterial load quantification.

## Methods

### *Routine culture-based microbiological diagnostics*

At the Microbiology and Virology Unit of “Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino” (Turin, Italy) respiratory samples were subjected to Gram staining and culture on appropriate solid medium at the time of arrival to the lab. MALDI-TOF MS analysis was used for bacterial identification and antimicrobial susceptibility testing was carried out on overnight subcultures using Microscan WalkAway plus System (Beckman Coulter, Brea, CA, USA) according to the manufacturer's instructions. Antimicrobial susceptibilities were interpreted according to EUCAST breakpoints as updated in 2019 [16]. The Total ESBL Confirm kit (Rosco, Taastrup, Denmark) was used to identify ESBL production if cefotaxime (CTX) and/or ceftazidime (CAZ) minimal inhibitory concentrations (MICs) were > 1 mg/l. The Mastdiscs<sup>®</sup> combi Carba plus disc system (Mast Group Ltd, Bootle, UK) was used to assess carbapenemase producers when meropenem (MP) MIC was > 0.125 mg/l. Detection of carbapenem resistance genes was performed using the Xpert Carba-R assay (Cepheid, Sunnyvale, CA, USA).

### *Specimen collection and study design*

Respiratory samples included in the study were those submitted for standard of care bacterial culture from January to June 2019. They were selected randomly based on sample type, integrity and amount of remnant specimen. Lower respiratory tract specimens included: sputum, tracheal aspirate (TA), bronchoaspirate (BA) and bronchoalveolar lavage (BAL). The administration of antibiotics before specimen collection was not assessed.

The ELITE MGB<sup>®</sup> assays were performed directly on 354 respiratory specimens sampled from 318 patients. The CRE and ESBL ELITE MGB<sup>®</sup> kits were assayed on sputum (n=7), TA (n=16), BA (n=16) and BAL (n=202), and the MRSA/SA ELITE MGB<sup>®</sup> kit was tested on sputum (n=35), TA (n=25), BA (n=15) and BAL (n=38). Two-hundred µl previously heated in a thermoblock at 90°C for 5 minutes of a 1:4 dilution in dithiothreitol solution (Sputasol, Oxoid Ltd, Basingstoke, United Kingdom) were used for sputum, TA and BA, whereas 200 µl of a 1:2 dilution in dithiothreitol solution were used for BAL. The ELITE MGB<sup>®</sup> kits internal control and positive and negative controls were used as previously described [10]. Total ELITE MGB assay test run time is 2 h 12 min with data analysis available immediately after the run. ELITE MGB<sup>®</sup> assays total cost includes reagents (approximately £25 per sample including DNA extraction), staff time and platform ELITE InGenius<sup>®</sup> rental.

Molecular results were then compared to routine culture-based microbiological diagnostics results to estimate the accuracy of genotypic analysis. Molecular results for the CRE, ESBL and MRSA/SA targets were interpreted as shown in Table 1. All cycles with a Ct value > 35 were considered negative for detectable signal. Presence of *S. aureus* and *mecA/C* targets at the same relative quantity ( $\Delta$ Ct between the two targets < 2) was considered indicative of MRSA (to mitigate against the potential for detection of methicillin-susceptible *S. aureus* together with methicillin-resistant coagulase-negative staphylococci).

Ct values were also compared to the quantitative culture results in order to maximize the potential clinical impact of molecular results.

This study was conducted in accordance with the Declaration of Helsinki. Formal ethical approval was not required by our Centre's institutional review board since the samples were anonymized and de-identified before being obtained by the study team.

### ***Statistical analysis***



Accuracy, sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of the CRE, ESBL and MRSA/SA ELITE MGB<sup>®</sup> kits with 95% confidence interval (CI 95%) were computed.

The Shapiro-Wilk test was performed to verify the normality of distribution of quantitative variables. Analysis of variance (ANOVA) with Bonferroni correction was carried out to assess whether significant differences in Ct values could be detected among quantitative culture groups (negative; 1,000-10,000 CFU/ml; >25,000 CFU/ml for carbapenemase- and ESBL-producers EB; negative; 1,000-10,000 CFU/ml; 10,000-50,000 CFU/ml; >50,000 CFU/ml for *S. aureus*).

p values of less than 5% were considered significant.

All analyses were performed with Stata 14.

## Results

### *Detection of carbapenemase, CTX-M and S. aureus and mecA/C genes*

Table 2 shows the comparison between molecular and conventional phenotypic results.

Among the 241 clinical specimens, *bla*<sub>KPC-like</sub> was detected in 29 (12%) specimens by the CRE ELITE MGB<sup>®</sup> kit. Twenty-two (75.9%) of these samples were confirmed by culture. Five of the 7 false-positive samples were from patients who became culture-positive for KPC-producing *K. pneumoniae* (TA n=2; BA n=1; urine culture n=1; rectal swab n=1) in the subsequent 7 days. *bla*<sub>CTX-M-like</sub> was detected in 26 (10.8%) specimens by the ESBL ELITE MGB<sup>®</sup> kit, of which 21 (80.8%) were confirmed by culture. Two of the 5 false-positive samples were from patients who ESBL-producing *K. pneumoniae* (blood culture n=1; urine culture n=1) isolated in the subsequent 7 days. The corresponding cultures of the two false-negative samples grew ESBL-producing *K. pneumoniae* and ESBL-producing *K. oxytoca* at quantities of 25,000-50,000 CFU/ml. No other ESBL- or carbapenemase-producing Gram-negative bacteria were detected by either molecular or culture-based testing.

ELITe MGB<sup>®</sup> kit detected *S. aureus* in 82/113 (72.6%) specimens, all of which were confirmed by culture. There was one false-negative sample, which gave a Ct value of 38.2, and a semi-quantitative culture result of 10,000-50,000 CFU/ml. Among the 83 culture-positive *S. aureus* samples, the *mecA/C* target was found in 23. The two presumed false positive samples by PCR may reflect the limitations of methicillin resistance phenotypic detection [17] or the presence of mixed populations of bacteria. The false negative sample showed  $\Delta Ct=2.61$  and culture-based diagnostics showed a mixed population of MRSA and methicillin resistant CoNS.

The Ct values determined by CRE, ESBL and MRSA/SA ELITe MGB<sup>®</sup> kits were compared to the bacterial loads obtained by conventional culture-based approach, (see supplementary material, Figure 1 and 2). The mean Cts obtained by CRE, ESBL ELITe MGB<sup>®</sup> kits were significantly different ( $p<0.05$ ) between culture negative and  $>25,000$  CFU/ml groups. With the MRSA/SA ELITe MGB<sup>®</sup> kit mean Cts between each quantitative culture group were found significantly different ( $p<0.05$ ) except between groups of 1,000-10,000 CFU/ml and 10,000-50,000 CFU/ml.

## Discussion

Conventional culture-based diagnostics has limitations in tackling the dissemination of multidrug resistant pathogens and in optimizing antibiotic therapy in patients with BLRTI in a timely manner. Molecular assays have the potential to perform a role as a more accurate and sensitive decision-making tool expediting infection control practices and supporting efforts to curtail inappropriate antibiotic use [12, 18-19].

This study represents one of the largest performance assessments of molecular assays detecting the main antibiotic resistance genes directly from clinical respiratory samples. High negative predictive values, but more variable positive predictive values were found. Several molecular assays of microbiological respiratory diagnostics focused on rapid pathogen identification but few data on rapid antibiotic resistance have been reported, other than for MRSA [15, 20-22]. The CRE and ESBL ELITe MGB<sup>®</sup> kits were particularly suited for the Italian and European epidemiology, since

the selection of these samples represents a picture of the most prevalent carbapenemase- and ESBL-EB [23]. However, limited number of enzymes tested for would need to be considered if these tests were implemented into clinical practice. Our data indicate that the MRSA/SA ELITE MGB<sup>®</sup> kit, when *S. aureus* and *mec* genes are detected at the same relative quantities in the presence of clinical signs of BLRTI could be of value in guiding the need for anti-MRSA therapy.

The potential role of molecular assays in surveillance, infection control practices and early optimization of antibiotic therapy is well known [12,24,25]. In particular, rapid availability of molecular results can not only facilitate early appropriate antibiotic therapy for patients with multidrug resistant (MDR) bacterial infection, but can also guide earlier de-escalation of antibiotic therapy for patients with negative results. Accuracy rates of the ELITE MGB<sup>®</sup> assays confirm that molecular approach together with the knowledge of local epidemiology susceptibility patterns could be used to expedite optimization of empirical antibiotic therapy and infection control practices in patients with BLRTI, especially when providing positive results for targeted antibiotic resistance genes. However, conventional culture-based antimicrobial susceptibility testing continues to be required both to confirm molecular results and to detect other antibiotic resistance mechanisms.

Nucleic acid amplification techniques cannot distinguish between living and dead bacteria [26]. The degree of correlation between bacterial load and Ct values could be conditional on factors affecting the viability of bacteria at the time of sampling (prior antibiotic treatment, immune-mediated bacterial death [27]), as well as potentially the presence of multiple copies of the same gene on mobile genetic elements [28,29]. In spite of these limitations, this study showed how Ct analysis may deliver some information about bacterial load.

Our study has several limitations, the main one being the lack of clinical data and prospective assessment of direct implications of molecular results on antimicrobial stewardship and clinical outcome. The administration of antibiotics before sampling was not known and this factor might have hampered the overall evaluation of the molecular false positive results. Nevertheless, we

believe that this study does show the potential for the use of CRE, ESBL and MRSA/SA ELITE MGB<sup>®</sup> kits to support infection control and antibiotic stewardship programmes in patients with a high suspicion of MDR BLRTI infection. Any future studies of the effectiveness of this approach will need to consider the feasibility of producing results in a timely manner (testing requires around 30 minutes of laboratory hands-on time and a test run time of around 3 hours), as well as the willingness of clinicians to respond to the results. All of these results would in turn have to feed into an assessment of the cost-effectiveness.

## Conclusions

In the smart era of resistance profiling the ELITE MGB<sup>®</sup> assays showed reasonable accuracy for the detection of carbapenemase- and ESBL-producing EB and MRSA in respiratory samples. These tests might be a useful complementary tool for expediting optimization of empirical antibiotic therapy and infection control practices in patients with BLRTI, depending on local prevalences of antibiotic resistance. However, further studies are required to confirm our results, to determine robust Ct cut-off values for colonization *vs.* infection, and to determine their clinical and cost effectiveness in routine clinical practice are required.

## Acknowledgements

**Funding:** no funding was received for this study.

**Conflict of Interest:** the authors declare that they have no conflict of interest.

## References

1. Naghavi M, Wang H, Lozano, R, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; 385: 117–71.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. *Am J Respir Crit Care Med* 2002;165:867–903. <http://dx.doi.org/10.1164/ajrccm.165.7.2105078>.
3. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388–416. <http://dx.doi.org/10.1164/rccm.200405-644ST>.
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax* 2012; 67: 71–9.
5. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. *Postgrad Med* 2010; 122: 130–41.
6. Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. *Int J Antimicrob Agents* 2011; 38: 108–17.
7. Ewig S, Torres A. Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. *Eur Respir J* 2011; 38: 253–60.
8. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: QA UK cohort study. *Clin Infect Dis* 2011;53:107–13.
9. Bianco G, Boattini M, Iannaccone M, Sidoti F, Cavallo R, Costa C. Detection of antibiotic resistance genes from blood cultures: performance assessment and potential impact on antibiotic therapy management. *J Hosp Infect* 2019;102:465-9. doi: 10.1016/j.jhin.2019.03.007.

10. Girlich D, Bernabeu S, Fortineau N, Dortet L, Naas T. Evaluation of the CRE and ESBL ELITE MGB<sup>®</sup> kits for the accurate detection of carbapenemase- or CTX-M-producing bacteria. *Diagn Microbiol Infect Dis* 2018;92:1-7. doi: 10.1016/j.diagmicrobio.2018.02.001.
11. Wang H, Hecht S, Kline D, Leber AL. Staphylococcus aureus and methicillin resistance detection directly from pediatric samples using PCR assays with differential cycle threshold values for corroboration of methicillin resistance. *J Microbiol Methods* 2019;159:167-73. doi: 10.1016/j.mimet.2019.01.009.
12. Paonessa JR, Shah RD, Pickens CI, Lizza BD, Donnelly HK, Malczynski M, et al. Rapid Detection of Methicillin-Resistant Staphylococcus aureus in BAL: A Pilot Randomized Controlled Trial. *Chest* 2019;155:999-1007. doi:10.1016/j.chest.2019.02.007.
13. Burillo A, Marín M, Cercenado E, Ruiz-Carrascoso G, Pérez-Granda MJ, Oteo J, et al. Evaluation of the Xpert Carba-R (Cepheid) Assay Using Contrived Bronchial Specimens from Patients with Suspicion of Ventilator-Associated Pneumonia for the Detection of Prevalent Carbapenemases. *PLoS One* 2016;11:e0168473. doi: 10.1371/journal.pone.0168473.
14. Cercenado E, Marín M, Burillo A, Martín-Rabadán P, Rivera M, Bouza E. Rapid detection of Staphylococcus aureus in lower respiratory tract secretions from patients with suspected ventilator-associated pneumonia: evaluation of the Cepheid Xpert MRSA/SA SSTI assay. *J Clin Microbiol* 2012;50:4095-7. doi: 10.1128/JCM.02409-12.
15. Ullberg M, Lüthje P, Mölling P, Strålin K, Özenci V. Broad-Range Detection of Microorganisms Directly from Bronchoalveolar Lavage Specimens by PCR/Electrospray Ionization-Mass Spectrometry. *PLoS One* 2017;12:e0170033. doi:10.1371/journal.pone.0170033.
16. EUCAST 2019. [www.eucast.org](http://www.eucast.org)
17. Kriegeskorte A, Idelevich EA, Schlattmann A, Layer F, Strommenger B, Denis O, et al. Comparison of Different Phenotypic Approaches to Screen and Detect mecC-Harboring Methicillin-Resistant Staphylococcus aureus. *J Clin Microbiol* 2017;56. pii: e00826-17. doi: 10.1128/JCM.00826-17.

18. Torres A, Lee N, Cilloniz C, Vila J, Van der Eerden M. Laboratory diagnosis of pneumonia in the molecular age. *Eur Respir J* 2016;48:1764-78. doi:10.1183/13993003.01144-2016.
19. Douglas IS. New diagnostic methods for pneumonia in the ICU. *Curr Opin Infect Dis* 2016;29:197-204. doi: 10.1097/QCO.0000000000000249.
20. Jamal W, Al Roomi E, AbdulAziz LR, Rotimi VO. Evaluation of Curetis Unyvero, a multiplex PCR-based testing system, for rapid detection of bacteria and antibiotic resistance and impact of the assay on management of severe nosocomial pneumonia. *J Clin Microbiol* 2014;52:2487-92. doi: 10.1128/JCM.00325-14.
21. Pulido MR, Moreno-Martínez P, González-Galán V, Fernández Cuenca F, Pascual Á, Garnacho-Montero J, et al. Application of BioFire FilmArray Blood Culture Identification panel for rapid identification of the causative agents of ventilator-associated pneumonia. *Clin Microbiol Infect* 2018;24:1213.e1-1213.e4. doi: 10.1016/j.cmi.2018.06.001.
22. Sansot M, Fradin E, Chenouard R, Kempf M, Kouatchet A, Lasocki S, et al. Performance of the extended use of the FilmArray(®) BCID panel kit for bronchoalveolar lavage analysis. *Mol Biol Rep* 2019;46:2685-92. doi: 10.1007/s11033-019-04710-0.
23. Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M  $\beta$ -lactamases: temporal and geographical shifts in genotype. *J Antimicrob Chemother* 2017;72:2145-55. doi: 10.1093/jac/dkx146.
24. Saliba R, Aho Glélé LS, Sarkis DK, Zahar JR. Evaluation of PCR assays for direct screening of Carbapenemase-Producing Enterobacteriaceae (CPE) from rectal swabs: a diagnostic meta-analysis. *J Hosp Infect* 2019. pii: S0195-6701(19)30487-6. doi: 10.1016/j.jhin.2019.11.017.
25. van Belkum A, Rochas O. Laboratory-Based and Point-of-Care Testing for MSSA/MRSA Detection in the Age of Whole Genome Sequencing. *Front Microbiol* 2018;9:1437. doi: 10.3389/fmicb.2018.01437.

26. Schulte B, Eickmeyer H, Heininger A, Juretzek S, Karrasch M, Denis O, et al. Detection of pneumonia associated pathogens using a prototype multiplexed pneumonia test in hospitalized patients with severe pneumonia. *PLoS One* 2014;9:e110566. doi:10.1371/journal.pone.0110566.
27. Guimaraes AO, Gutierrez J, Maskarinec SA, Cao Y, Hong K, Ruffin F, et al. Prognostic Power of Pathogen Cell-Free DNA in *Staphylococcus aureus* Bacteremia. *Open Forum Infect Dis* 2019;6:ofz126. doi: 10.1093/ofid/ofz126.
28. D'Andrea MM, Arena F, Pallecchi L, Rossolini GM. CTX-M-type  $\beta$ -lactamases: a successful story of antibiotic resistance. *Int J Med Microbiol* 2013;303:305-17. doi: 10.1016/j.ijmm.2013.02.008.
29. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2001;45:1151-61.



**Table 1.** Interpretation of molecular results on respiratory samples for the detection of carbapenemase, ESBL, *Staphylococcus aureus* and meticillin resistance encoding genes.

Interpretation		Report
CRE ELITE MGB® Kit	ESBL ELITE MGB® Kit	
+	-	Carbapenemase encoding gene KPC, NDM-IMP-VIM, OXA-48 DNA detected
+	+	Carbapenemase and ESBL encoding genes Both KPC, NDM-IMP-VIM, OXA-48 DNA detected and CTX-M <sub>s</sub> DNA detected
-	+	ESBL encoding gene CTX-M DNA detected
-	-	Nor carbapenemase neither ESBL encoding genes Neither KPC, NDM-IMP-VIM, OXA-48 nor CTX-M <sub>s</sub> DNA detected
MRSA/SA ELITE MGB® Kit		
<i>S. aureus</i>	<i>mecA/C</i>	
+	+	$\Delta Ct < 2$ , MRSA MRSA DNA detected
+	+	$\Delta Ct > 2$ , MSSA MSSA DNA detected
+	-	MSSA MSSA DNA detected
-	+	No <i>S. aureus</i> No <i>S. aureus</i> DNA detected
-	-	No <i>S. aureus</i> No <i>S. aureus</i> DNA detected

All cycles with a cycle threshold (Ct) value > 35 were considered negative;

ESBL - extended-spectrum  $\beta$ -lactamase, MSSA - meticillin susceptible *S. aureus*, MRSA - meticillin resistant *S. aureus*.

**Table 2.** Performance of the CRE, ESBL, MRSA/SA ELITE MGB kits on respiratory samples compared to conventional phenotypic results.

Conventional phenotypic results								
Respiratory samples n=241								
		Positive	Negative					
CRE, ESBL ELITe MGB® Kits				Accuracy	Sensitivity [CI 95%]	Specificity [CI 95%]	PPV [CI 95%]	NPV [CI 95%]
bla <sub>KPC</sub> -like	Positive	22	7	97.1%	100% [85.1-100]	96.8% [93.6-98.4]	75.9% [60.3-86.7]	100%
	Negative	0	212					
bla <sub>CTX-M</sub> -like	Positive	21	5	97.1%	91.3% [73.2-97.6]	97.7% [94.7-99]	80.8% [63.6-91]	99.1% [96.6-99.8]
	Negative	2	213					
Respiratory samples n=113								
		Positive	Negative					
MRSA/SA ELITe MGB® Kit				Accuracy	Sensitivity [CI 95%]	Specificity [CI 95%]	PPV [CI 95%]	NPV [CI 95%]
S. aureus	Positive	82	0	99.2%	98.8% [93.5-100]	100% [88.7-100]	100%	96.8% [81.6-99.5]
	Negative	1	30					
mecA/C	Positive	22	2	96.4%	95.7% [79-99.2]	96.7% [88.6-99.1]	91.7% [73.7-97.7]	98.3% [89.8-99.3]
	Negative	1	58					

PPV – positive predictive value; NPV – negative predictive value.